Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from AC Immune SA ( (ACIU) ) is now available.
On June 11, 2025, AC Immune SA announced the promotion of Dr. Günther Staffler to the interim role of Executive Vice President, Development. Dr. Staffler, who joined the company in 2021, will oversee the development of AC Immune’s active immunotherapies. This leadership change follows the departure of Dr. Anke Post, the Chief Medical Officer, and is expected to influence the company’s strategic direction in advancing its clinical programs.
The most recent analyst rating on (ACIU) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
AC Immune SA’s overall stock score is primarily influenced by its moderate financial performance and mixed technical indicators. Persistent net losses and a challenging valuation weigh heavily on the score. While short-term technical momentum is positive, longer-term trends and valuation concerns suggest caution.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a biotechnology company based in Lausanne, Switzerland, specializing in the development of active immunotherapies for central nervous system diseases. The company focuses on advancing treatments targeting amyloid beta and a-synuclein, among other neurological targets.
Average Trading Volume: 155,505
Technical Sentiment Signal: Sell
Current Market Cap: $217.7M
Learn more about ACIU stock on TipRanks’ Stock Analysis page.